Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

BioMarin typically reports earnings after market close, meaning Day 0 reflects pre-announcement anticipation while Day +1 captures the market's first full reaction to results.

Historical price action shows moderate Day 0 moves averaging 2.13% as the market positions ahead of results, followed by larger Day +1 reactions averaging 2.88% once investors digest the actual numbers. However, the Day +1 range of 7.11% reveals significant intraday volatility, with the stock often swinging dramatically as traders reassess the quarter's implications.

Recent earnings have produced mixed directional outcomes. The most recent report (August 2026) generated a +2.59% Day 0 move and +3.82% Day +1 gain, rewarding the strong beat. In contrast, May 2026 saw a +2.59% Day 0 anticipation move reverse sharply to a -4.00% Day +1 decline despite the stock initially rallying, suggesting investors found something disappointing in the details or guidance. The October 2025 report—the year-ago Q3—produced a -3.32% Day 0 drop that partially recovered with a +1.56% Day +1 bounce, reflecting the initial shock of the miss followed by bargain-hunting.

The 3.86% average Day 0 range and 7.11% average Day +1 range indicate BMRN experiences substantial two-day volatility around earnings, with the Day +1 session typically determining the ultimate direction as the market fully processes results and guidance.

Part 2.2: Options Market Expected Move

The options market is pricing a 7.52% expected move through the November 20 expiration, significantly higher than the 2.88% average Day +1 move but roughly in line with the 7.11% average Day +1 range observed historically. This suggests options traders are anticipating above-average volatility, likely reflecting uncertainty around BioMarin's ability to sustain profitability and the wide dispersion in analyst estimates.

Part 3: What Analysts Are Saying

Analyst sentiment on BioMarin remains strongly bullish despite recent stock weakness, with the consensus "Moderate Buy" rating supported by an overwhelming 20 Strong Buy recommendations versus just 8 Holds and zero sell ratings among 28 analysts. The average price target of $90.37 implies 61% upside from the current $55.95 price, with the high estimate of $122.00 suggesting some analysts see potential for the stock to more than double.

Sentiment has improved over the past month, with Strong Buy ratings increasing from 18 to 20 while Moderate Buys declined from 1 to 0 and Holds rose modestly from 7 to 8. The average recommendation of 4.43 (on a 5-point scale where 5 is Strong Buy) reflects conviction that BioMarin's rare disease franchise and improving profitability trajectory justify significantly higher valuations. The target range of $58.00 to $122.00 reveals divergent views on execution risk, but even the low-end target implies modest upside from current levels.

The analyst community's optimism stands in notable contrast to the stock's recent technical deterioration, suggesting the Street views current weakness as a buying opportunity ahead of what many expect will be a strong Q3 report and improved forward guidance.

Part 4: Technical Picture

BioMarin's technical setup heading into earnings reflects deteriorating momentum despite trading near short-term support levels. The Barchart Technical Opinion currently shows a 40% Sell signal, unchanged from last week but representing a significant reversal from the 56% Buy signal just one month ago. This rapid shift from bullish to bearish reflects the stock's recent decline from its $70.98 52-week high to current levels near $55.95.

Timeframe Analysis:

• Short-term (100% Sell): Maximum bearish signal indicates immediate-term momentum has turned decisively negative, suggesting near-term traders are positioned defensively ahead of earnings
• Medium-term (50% Buy): Neutral-to-slightly-bullish reading suggests the intermediate trend remains constructive despite recent weakness, indicating the pullback may be viewed as a correction within an intact uptrend
• Long-term (50% Sell): Moderate bearish signal reflects concern about the longer-term trajectory, though the neutral 50% reading suggests the trend hasn't definitively broken down

Trend Characteristics: The Weak strength combined with Weakening direction indicates BioMarin is experiencing deteriorating technical conditions with limited conviction, creating an uncertain environment heading into the earnings release.

The stock is trading at $55.95, positioned above its 5-day ($55.78) and 10-day ($56.41) moving averages but below all longer-term averages including the 20-day ($56.41), 50-day ($61.71), 100-day ($60.51), and 200-day ($58.46). This configuration—above very short-term support but below all meaningful trend indicators—suggests BMRN is attempting to stabilize after a significant decline but hasn't yet established a sustainable recovery pattern. The stock is trading near its 52-week low of $49.26 and well off its $70.98 high, with the $54.08 recent low representing critical support. The technical setup is cautionary heading into earnings: while oversold conditions could fuel a relief rally on good news, the weak momentum and position below key moving averages leave the stock vulnerable to further downside if results or guidance disappoint. The 100% short-term sell signal suggests traders are positioned defensively, potentially creating opportunity for a sharp reversal if BioMarin delivers a strong beat and raises guidance.